Skip to content

Study · Not a test of the peptide alone · 2005

2 results

Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study.

Miyagawa Y, Tsujimura A, Matsumiya K, Takao T, Tohda A, Koga M, Takeyama M, Fujioka H, Takada S, Koide T, Okuyama A

The Journal of urology1 Jun 2005Cited by 59 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking hCG (human chorionic gonadotropin).

  1. 01HumanNot a test of hCG (human chorionic gonadotropin) aloneObservational studyEfficacy outcome

    In men with hypogonadotropic hypogonadism and small testes, hCG/hMG treatment resulted in sperm production in 36%.

    In plain wordsIn men with hypogonadotropic hypogonadism and small testes, combined hCG and hMG treatment was linked to sperm production in 36%.

    Outcome
    IncreaseSperm production in small-testis subset
    Study

    n = 23

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Subjects with sperm production
    36%
    small-testis subset during hCG/hMG treatment

    Source sentences

    Summary
    Long-term administration of hCG/hMG for 12 to 240 months (average 56 +/- 11) resulted in sperm production in only 36% of the small testis subjects but in 71% of the large testis subjects.
    2 context sentences
    Summary · context
    Medical charts of 36 male patients (age range 11 to 42 years) with HH (81% primary, 19% secondary) treated at university affiliated male infertility centers were reviewed.
    Summary · context
    Pubic hair stage, genital stage, testicular volume (TV), sexual function and sperm production were determined before and after human chorionic gonadotropin/human menopausal gonadotropin (hCG/hMG) treatment.

    In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).

  2. 02HumanNot a test of hCG (human chorionic gonadotropin) aloneObservational studyEfficacy outcome

    In men with hypogonadotropic hypogonadism and large testes, hCG/hMG treatment resulted in sperm production in 71%.

    In plain wordsIn men with hypogonadotropic hypogonadism and large testes, combined hCG and hMG treatment was linked to sperm production in 71%.

    Outcome
    IncreaseSperm production in large-testis subset
    Study

    n = 13

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Subjects with sperm production
    71%
    large-testis subset during hCG/hMG treatment

    Source sentences

    Summary
    Long-term administration of hCG/hMG for 12 to 240 months (average 56 +/- 11) resulted in sperm production in only 36% of the small testis subjects but in 71% of the large testis subjects.
    2 context sentences
    Summary · context
    Medical charts of 36 male patients (age range 11 to 42 years) with HH (81% primary, 19% secondary) treated at university affiliated male infertility centers were reviewed.
    Summary · context
    Pubic hair stage, genital stage, testicular volume (TV), sexual function and sperm production were determined before and after human chorionic gonadotropin/human menopausal gonadotropin (hCG/hMG) treatment.

    In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.